Nashville, Tennessee Clinical Trials

A listing of Nashville, Tennessee clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 64 clinical trials
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

liquid biopsy
folic acid
adjuvant therapy
stage iv non-small cell lung cancer
pemetrexed
Tennessee Oncology - Nashville (SCRI)
 (1.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +27 other locations
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Endocrine therapy is the initial treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancers. This study will evaluate the use of venetoclax in combination with capecitabine in adult participants with HR+, HER2-, metastatic breast cancer (MBC) who had disease progression following treatment …

epidermal growth factor
venetoclax
primary tumor
capecitabine
erbb2
Vanderbilt University Med Ctr /ID# 213852
 (2.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +15 other locations
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

estrogen receptor
epidermal growth factor
cancer
breast cancer
her2/neu-negative breast cancer
Tennessee Oncology
 (1.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +6 other locations
A Study of AK104 a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.

squamous cell carcinoma
bevacizumab
metastasis
formalin-fixed paraffin-embedded
adenosquamous carcinoma
Sarah Cannon Research Institute
 (1.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +19 other locations
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

seribantumab
indirect bilirubin
neutrophil count
direct bilirubin
formalin-fixed paraffin-embedded
Sarah Cannon Research Institute
 (1.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.

measurable disease
alopecia
lung cancer
fallopian tube
cancer
Sarah Cannon Research Institute (SCRI)
 (1.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +2 other locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

measurable disease
combination therapy
docetaxel
enzalutamide
cancer
Tennessee Oncology - Nashville
 (1.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +21 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

imiglucerase
deficiency
eliglustat
gaucher disease
Investigational Site Number 840049
 (0.3 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +208 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

deficiency
replacement therapy
glycogen storage disease type ii
gaa gene
myozyme
Investigational Site Number 840049
 (0.3 away) Contact site
  • 0 views
  • 22 Dec, 2020
  • +168 other locations
Fabry Disease Registry & Pregnancy Sub-registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary …

deficiency
replacement therapy
fabrazyme
agalsidase beta
alpha-galactosidase
Investigational Site Number 840049
 (0.3 away) Contact site
  • 0 views
  • 22 Dec, 2020
  • +125 other locations